Stroke patients treated intravenously with loberamisal, a novel neuroprotective medication, daily for 10 days and starting within 48 hours of stroke symptoms, had better recovery than patients who received a placebo, according to a preliminary late-breaking science presentation at the American Stroke Association’s International Stroke Conference 2026.